This study examines the prevalence and outcomes of diabetes, hypertension, and cardiovascular disease in patients with chronic obstructive pulmonary disease (COPD). Data from the Atherosclerosis Risk in Communities Study (ARIC) and the Cardiovascular Health Study (CHS) were analyzed, focusing on subjects aged 45 years and older. The study found that lung function impairment was associated with a higher prevalence of comorbid diseases, including diabetes, hypertension, and cardiovascular disease. In logistic regression models, subjects with GOLD stage 3 or 4 COPD had a higher risk of these comorbidities (odds ratios: diabetes 1.5, hypertension 1.6, cardiovascular disease 2.4). Comorbid diseases were associated with increased hospitalization and mortality risks, particularly in those with impaired lung function. The study highlights the importance of addressing comorbidities in patients with COPD to improve outcomes.This study examines the prevalence and outcomes of diabetes, hypertension, and cardiovascular disease in patients with chronic obstructive pulmonary disease (COPD). Data from the Atherosclerosis Risk in Communities Study (ARIC) and the Cardiovascular Health Study (CHS) were analyzed, focusing on subjects aged 45 years and older. The study found that lung function impairment was associated with a higher prevalence of comorbid diseases, including diabetes, hypertension, and cardiovascular disease. In logistic regression models, subjects with GOLD stage 3 or 4 COPD had a higher risk of these comorbidities (odds ratios: diabetes 1.5, hypertension 1.6, cardiovascular disease 2.4). Comorbid diseases were associated with increased hospitalization and mortality risks, particularly in those with impaired lung function. The study highlights the importance of addressing comorbidities in patients with COPD to improve outcomes.